Hubly Surgical™
Hubly Surgical™ is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Hubly Surgical™.
Hubly Surgical™ is a company.
Key people at Hubly Surgical™.
Hubly Surgical is a neurosurgical device company developing innovative electric drill systems to enhance safety in bedside cranial access procedures, targeting the high complication rates—up to 20% lethal—in skull punctures performed 100,000 times annually in the US.[1][3][4] Their flagship Hubly Drill + Cranial Access Kit (also called Hubly Ventri Drill) serves neurosurgeons in hospitals and underserved settings, solving risks like hemorrhage, stroke, and brain injury from over-drilling by incorporating plunge protection, auto-retraction, drilling guidance, and battery power for emergency use outside operating rooms.[1][2][3][4][5] With FDA 510(k) clearance achieved in May 2023, the company has transitioned to commercial sales, trialed units at institutions like Johns Hopkins, expanded to a 2.7mm drill bit for ICP monitor placement, and covers sales reps across continental US states, projecting strong growth including a Hubly Spine Drill submission.[2][3]
Hubly Surgical was co-founded in 2019 by CEO Casey Qadir (née Grage), a neuroscientist from Northwestern University whose passion stemmed from her grandfather's Parkinson's disease and volunteer work at Georgetown Stroke Clinic, where she identified high failure rates in traditional hand-crank drills for skull punctures.[1][3][4][5] As a neuroscience student in 2017, Qadir researched Parkinson's, built neuro-implantable devices, analyzed neurosurgical data with physicians, and worked in JP Morgan's Big Data and NASA's neuroengineering roles before launching Hubly.[3][4][5] Key team members include VP of Technology Tyler Panian (10+ years medtech, 20+ patents), neurosurgeon Dr. Ayer (MBA from Northwestern, co-founder of Rhaeos), and experts in regulatory, quality, software, and commercial medtech with 100+ combined years.[2][4][5] Early traction came from Northwestern's Farley Center, partnerships like Ontogen Medtech for FDA clearance, and pilots at Stanford, Northwestern, UT Health, and Johns Hopkins, marking the shift from prototype to market-ready in 2023.[1][2][3][4]
Hubly rides the neurotechnology and medtech safety wave, addressing billion-dollar complications in bedside neurosurgery amid post-COVID hospital cost pressures and OR shortages, where 20% failure rates in skull punctures endanger lives and inflate expenses.[1][2][4] Timing aligns with FDA accelerations for innovative devices and demand for underserved settings, enabling faster interventions for hemorrhage/stroke patients.[2][3][5] Market tailwinds include aging populations driving neurological procedures and shifts to cost-effective, portable tech over OR dependency.[1][3] Hubly influences the ecosystem by modernizing archaic tools, inspiring safer drilling standards, and paving expansion to spinal/epidural applications, potentially acquired by giants like Medtronic.[3][4]
Hubly's FDA milestone and US-wide sales signal commercial acceleration, with a submitted Hubly Spine Drill poised for clearance to broaden safer procedures beyond cranium.[3] Trends like AI-guided medtech, telehealth integration, and value-based care will amplify their plunge-proof tech, targeting $20M+ Year 1 revenue from pipeline hospitals.[4] Influence may evolve via acquisition or Series B scaling, solidifying surgical safety for all—echoing their origin in reducing lethal risks that sparked Casey's mission.[1][3][5]
Key people at Hubly Surgical™.
